RPG Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
RPG Life Sciences' recent management commentary and industry dynamics suggest a stable outlook for revenue growth and margins. The company's focus on developing innovative products and biosimilars aligns with the broader industry trend of improving pricing power and expanding market opportunities. Despite facing some margin pressures due to rising input costs, the overall sentiment remains positive, supported by a robust pipeline and favorable currency dynamics. Vista's financial outlook reflects expectations of stable revenue growth consistent with historical performance, alongside stable profit margins. The company's conservatively financed balance sheet, characterized by a low debt-to-equity ratio, enhances its financial stability, allowing for strategic capital allocation. While the Indian pharmaceutical sector is experiencing growth, driven by strong demand for chronic therapies and favorable regulatory conditions, RPG Life Sciences must navigate potential headwinds from cyclical pressures in key markets. Over the next 12-24 months, the focus on innovative therapies and export opportunities presents significant growth potential, although investors should remain vigilant regarding margin sustainability and competitive positioning within a fragmented market. Overall, Vista's forecast indicates a fair valuation, with a target price reflecting limited upside in the near term
Why We Like This Stock
Things To Watch Out For
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 582 | 653 | 708 | 733 | 739 |
| Profit Before Tax (Cr.) | 117 | 147 | 150 | 155 | 156 |
| PBT Margin | 20.1% | 22.5% | 2120.1% | 21.1% | 21.1% |
| Net Profit (Cr.) | 87 | 115 | 116 | 120 | 122 |
| Earnings Per Share | 52.7 | 69.7 | 70.5 | 73.0 | 73.7 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.